Dr Vasileios Angelis

Qualifications

MRCP (Onc), MBChB, PhD, BSc

GMC number: 7271308

Practising since: 2012

Specialties

Medical Oncology

Sub-specialties: Breast

Consultation times

  • Friday PM
  • Overview
Enquire now

Or call us on

07501 323 831

About

I see private patients at The Holly Private Hospital and offer specialist consultation, diagnosis, and ongoing cancer care in a dedicated and supportive environment.

Conditions treated

  • Breast cancer (all stages)
  • Early-stage breast cancer
  • Advanced / metastatic breast cancer
  • Breast cancer in young women
  • Hormone receptor–positive breast cancer
  • HER2-positive breast cancer
  • Triple-negative breast cancer.

Treatments and services

  • Comprehensive consultations and diagnostic review
  • Personalised treatment planning
  • Chemotherapy
  • Hormonal (endocrine) therapy
  • Targeted therapies
  • Immunotherapy
  • Access to clinical trials (where appropriate)
  • Second opinions on diagnosis and treatment plans.

Specialist expertise

  • Systemic (drug-based) cancer treatments
  • Complex case assessment and treatment planning
  • Management of treatment side effects
  • Evidence-based, research-led care.

Patient-centred approach

  • Individualised treatment tailored to your specific situation
  • Clear and honest communication at every stage
  • Support in understanding your diagnosis and options
  • Continuity of care and regular follow-up
  • Compassionate, respectful support throughout your journey.


Doctify:
Dr Vasileios Angelis

Special interests

  • Triple negative breast cancer
  • Cancer in younger women.

Languages spoken

English, Greek

Treatments and tests offered by Dr Vasileios Angelis at Nuffield Health

  • Colorectal screening
  • Electrocardiogram (ECG)
  • Liver biopsy
  • Breast oncology

Locations Dr Vasileios Angelis works with

Related experience

Research

Systemic Therapies for HER2-Positive Advanced Breast Cancer - PubMed

The Management of ER-Low, HER2-Negative Breast Cancer in the United Kingdom: A Survey of Current Clinical Practice - PubMed

State of the art: Targeting microsatellite instability in gastrointestinal cancers - PubMed

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries - PubMed

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study - PubMed

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer - PubMed

Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors - PubMed

Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer - PubMed

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study - PubMed

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer - PubMed

Memberships

  • European Society For Medical Oncology
  • American Society of Clinical Oncology

Other posts held

  • Medical Oncology Consultant, St Bartholomew’s Hospital

Insurers Dr Vasileios Angelis works with

Dr Vasileios Angelis works with the following private medical insurance providers:

  • Bupa Fee Assured
  • Bupa
  • AXA Health